Skip to main content
. 2023 Mar 1;41(3):388–403. doi: 10.1007/s00774-023-01403-4

Table 4.

Risk factors for hypocalcemia in patients with cancer after receiving denosumab

The first cycle of denosumab treatment
Renal insufficiency
Hypercalcemia before treatment
Aberrantly high baseline serum ALP
Higher baseline bone turnover markers of NTx and BSAP
Potential vitamin D deficiency

ALP alkaline phosphatase, NTx N-terminal cross-linking telopeptide of type 1 collagen, BSAP bone-specific alkaline phosphatase